459 related articles for article (PubMed ID: 33812492)
1. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
4. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
[TBL] [Abstract][Full Text] [Related]
5. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
[TBL] [Abstract][Full Text] [Related]
6. Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
Ishikawa H; Mutoh M; Abe T; Nakajima T; Takeuchi Y; Ezoe Y; Wakabayashi K; Doyama H; Sakai T
Pharmacology; 2019; 104(1-2):51-56. PubMed ID: 31067545
[TBL] [Abstract][Full Text] [Related]
7. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Burn J; Mathers J; Bishop DT
Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials.
Ishikawa H; Nakamura T; Kawano A; Gondo N; Sakai T
J Gastroenterol; 2009; 44 Suppl 19():77-81. PubMed ID: 19148798
[TBL] [Abstract][Full Text] [Related]
10. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
Burn J; Bishop DT; Chapman PD; Elliott F; Bertario L; Dunlop MG; Eccles D; Ellis A; Evans DG; Fodde R; Maher ER; Möslein G; Vasen HF; Coaker J; Phillips RK; Bülow S; Mathers JC;
Cancer Prev Res (Phila); 2011 May; 4(5):655-65. PubMed ID: 21543343
[TBL] [Abstract][Full Text] [Related]
11. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
Burn J; Sheth H; Elliott F; Reed L; Macrae F; Mecklin JP; Möslein G; McRonald FE; Bertario L; Evans DG; Gerdes AM; Ho JWC; Lindblom A; Morrison PJ; Rashbass J; Ramesar R; Seppälä T; Thomas HJW; Pylvänäinen K; Borthwick GM; Mathers JC; Bishop DT;
Lancet; 2020 Jun; 395(10240):1855-1863. PubMed ID: 32534647
[TBL] [Abstract][Full Text] [Related]
12. Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis.
Lynch PM
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):418-419. PubMed ID: 33812493
[No Abstract] [Full Text] [Related]
13. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
14. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
Chen YX; Gao QY; Zou TH; Wang BM; Liu SD; Sheng JQ; Ren JL; Zou XP; Liu ZJ; Song YY; Xiao B; Sun XM; Dou XT; Cao HL; Yang XN; Li N; Kang Q; Zhu W; Xu HZ; Chen HM; Cao XC; Fang JY
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):267-275. PubMed ID: 31926918
[TBL] [Abstract][Full Text] [Related]
15. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Asano TK; McLeod RS
Cochrane Database Syst Rev; 2004; 2004(2):CD004079. PubMed ID: 15106236
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
Stone JK; Mehta NA; Singh H; El-Matary W; Bernstein CN
Fam Cancer; 2023 Oct; 22(4):413-422. PubMed ID: 37119510
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.
Cruz-Correa M; Hylind LM; Marrero JH; Zahurak ML; Murray-Stewart T; Casero RA; Montgomery EA; Iacobuzio-Donahue C; Brosens LA; Offerhaus GJ; Umar A; Rodriguez LM; Giardiello FM
Gastroenterology; 2018 Sep; 155(3):668-673. PubMed ID: 29802852
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Burn J; Gerdes AM; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen HF; Barker G; Crawford G; Elliott F; Movahedi M; Pylvanainen K; Wijnen JT; Fodde R; Lynch HT; Mathers JC; Bishop DT;
Lancet; 2011 Dec; 378(9809):2081-7. PubMed ID: 22036019
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
